MedPath

SLEep APnea Screening Using Mobile Ambulatory Recorders After TIA/Stroke

Not Applicable
Completed
Conditions
Transient Ischemic Attack
Stroke
Obstructive Sleep Apnea
Interventions
Device: In-laboratory polysomnography
Device: Portable sleep monitor (ApneaLink Air)
Registration Number
NCT02454023
Lead Sponsor
Sunnybrook Health Sciences Centre
Brief Summary

Obstructive sleep apnea (OSA) is common after stroke/TIA and, left untreated, is associated with recurrent vascular events, poor functional outcomes, and long-term mortality. Despite its high prevalence, OSA often remains underdiagnosed after stroke. The purpose of this study is to evaluate portable sleep monitors (PSMs) as a broad screening tool for OSA after stroke/TIA. The study investigators hypothesize that the screening with PSMs will lead to an increase in the diagnosis of treatable OSA after stroke/TIA and an improvement in sleep-related and functional outcomes.

Detailed Description

Obstructive sleep apnea (OSA) is common after stroke and, left untreated, is associated with recurrent vascular events, poor functional outcomes, and long-term mortality. Despite its high prevalence, OSA often remains underdiagnosed after stroke. While in-laboratory polysomnography studies are the gold standard for diagnosing OSA, their use is limited by the lack of availability, patient unwillingness to sleep overnight at a laboratory and high costs. Home-based PSMs can accurately diagnose OSA and are much more accessible, convenient and low-priced compared to in-laboratory sleep studies.

The primary purpose of this study is to determine whether broad screening for OSA using PSMs, as compared to usual care, increases the proportion of patients diagnosed with treatable OSA after stroke or TIA. Secondary aims include whether screening with PSMs increases the proportion of patients treated for OSA with continuous positive airway pressure (CPAP) and whether functional outcomes and sleep-related outcomes are improved. Finally, the study will also determine whether this approach is cost-effective.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
250
Inclusion Criteria
  • Imaging-confirmed stroke or stroke-neurologist diagnosed TIA in the past 6-months, and
  • Outpatients being managed at the Sunnybrook Stroke Prevention clinic or inpatients on the Sunnybrook Stroke Unit.
Exclusion Criteria
  • Prior diagnosis of OSA
  • Current use of CPAP
  • Life expectancy less than 12 months
  • The presence of conditions known to compromise the accuracy of portable sleep monitoring, such as moderate to severe pulmonary disease or congestive heart failure
  • Oxygen therapy (eg. nasal prongs), a nasogastric tube, or other medical devices that would interfere with the placement of the sensors of the sleep monitoring device and/or CPAP
  • Physical impairment, aphasia, or language barrier restricting ability to complete study assessments, overnight sleep monitoring, and/or comply with CPAP therapy, and no caregiver available to assist the patient with the study requirements
  • Facial or bulbar weakness or trauma restricting the ability to create a seal with a CPAP mask
  • Pregnancy
  • Occupation that would make randomization to the standard of care arm unethical
  • Not covered by Ontario health insurance plan (OHIP)
  • Unable to attend follow-up assessments

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard of careIn-laboratory polysomnographyPatients receive usual standard of care for investigating obstructive sleep apnea after stroke/transient ischemic attack, which is in-laboratory polysomnography.
Portable sleep monitor (ApneaLink Air)Portable sleep monitor (ApneaLink Air)Patients will undergo screening for obstructive sleep apnea using the ApneaLink Air portable sleep monitor.
Primary Outcome Measures
NameTimeMethod
Proportion of patients diagnosed with treatable OSA6 & 12 months

Proportion of patients diagnosed with treatable OSA by 6 \& 12 months

Secondary Outcome Measures
NameTimeMethod
Proportion of patients prescribed CPAP for treatable OSA6 & 12 months

Proportion of patients prescribed CPAP for treatable OSA by 6 \& 12 months

Neurological outcomes (as assessed by the modified Rankin scale)6 months

Neurological outcomes (as assessed by the modified Rankin scale) at 6 months

Cost to deliver each management strategy and treatment6 months

Cost to deliver each management strategy and treatment by 6 months

Sleep-related quality of life (Functional Outcomes of Sleep Quality questionnaire)6 months

Sleep-related quality of life (Functional Outcomes of Sleep Quality questionnaire) at 6 months

Daytime sleepiness (Epworth Sleepiness Scale)6 & 12 months

Daytime sleepiness (Epworth Sleepiness Scale) at 6 \& 12 months

Neurological outcomes (as assessed by the National Institutes of Health stroke scale)6 months

Neurological outcomes (as assessed by the National Institutes of Health stroke scale) at 6 months

New vascular events (stroke, TIA, myocardial infarction, coronary artery stenting)12 months

Assessed via telephone call at 12 months

Neurological outcomes (as assessed by the Stroke Impact Scale)6 months

Neurological outcomes (as assessed by the Stroke Impact Scale) at 6 months

24-hr ambulatory blood pressure6 months

24-hr ambulatory blood pressure at 6 months

Trial Locations

Locations (1)

Sunnybrook Health Sciences Centre

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath